Bioness announces it has begun shipping the L300 Go System, cleared by the FDA in early 2017 and available in four configurations for use in patients with foot drop and/or muscle weakness related to upper motor neuron disease/injury.
The L300 Go System succeeds the NESS L300 Foot Drop System and NESS L300 Plus System, and includes numerous advancements designed to optimize therapy sessions and promote functional gains at home.
Among these is comprehensive 3D motion detection of gait events, via a learning algorithm that analyzes patient movement and offers electrical stimulation precisely when needed during the gait cycle.
Additional features, according to a media release from Valencia, Calif-based Bioness, include adaptive motion detection and onboard controls that eliminate dependence on foot sensors or remote controls; multi-channel stimulation, which enables clinicians to adjust dorsiflexion and inversion/eversion with a novel new electrode options; and myBioness, a new mobile iOS application designed to empower home users to extend rehabilitative gains through setting goals and tracking recovery progress.
“Today’s value-based healthcare model demands that rehabilitative professionals keep patients motivated through superior, more personalized care,” says Todd Cushman, president and CEO of Bioness, in the release. “With the introduction of the L300 Go, clinicians now have access to technological innovations that keep patients engaged during the recovery process while improving mobility in the clinic and community.”
Current users of the L300 Foot Drop System and the L300 Plus System will be eligible for a Customer Loyalty Upgrade Program, which is designed to make the L300 Go more accessible for users in the clinic and community.
[Source(s): Bioness, PR Newswire]
